Bamco Inc. NY increased its stake in shares of BioNTech SE (NASDAQ:BNTX - Free Report) by 88.6% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 18,574 shares of the company's stock after buying an additional 8,724 shares during the quarter. Bamco Inc. NY's holdings in BioNTech were worth $2,206,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also modified their holdings of the company. Baillie Gifford & Co. increased its holdings in BioNTech by 0.4% during the 3rd quarter. Baillie Gifford & Co. now owns 8,308,071 shares of the company's stock valued at $986,750,000 after purchasing an additional 31,773 shares in the last quarter. FMR LLC grew its stake in shares of BioNTech by 797.8% during the third quarter. FMR LLC now owns 6,299,929 shares of the company's stock worth $748,243,000 after purchasing an additional 5,598,190 shares during the period. Deerfield Management Company L.P. Series C grew its stake in shares of BioNTech by 4.3% during the second quarter. Deerfield Management Company L.P. Series C now owns 594,000 shares of the company's stock worth $47,734,000 after purchasing an additional 24,426 shares during the period. Candriam S.C.A. lifted its holdings in BioNTech by 261.2% during the second quarter. Candriam S.C.A. now owns 578,998 shares of the company's stock worth $46,526,000 after acquiring an additional 418,695 shares in the last quarter. Finally, Fred Alger Management LLC bought a new position in BioNTech during the third quarter worth about $59,485,000. Institutional investors own 15.52% of the company's stock.
Analyst Upgrades and Downgrades
BNTX has been the topic of a number of research reports. The Goldman Sachs Group upgraded BioNTech from a "neutral" rating to a "buy" rating and boosted their price target for the company from $90.00 to $137.00 in a report on Friday, November 8th. Evercore ISI raised BioNTech from an "in-line" rating to an "outperform" rating and upped their target price for the company from $110.00 to $125.00 in a research report on Tuesday, November 19th. JPMorgan Chase & Co. cut their target price on BioNTech from $124.00 to $122.00 and set a "neutral" rating for the company in a research note on Tuesday, November 26th. HC Wainwright restated a "buy" rating and set a $150.00 target price on shares of BioNTech in a research note on Monday, November 18th. Finally, Deutsche Bank Aktiengesellschaft upped their target price on BioNTech from $95.00 to $150.00 and gave the stock a "buy" rating in a research note on Thursday, September 19th. Four investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, BioNTech currently has an average rating of "Moderate Buy" and an average price target of $138.67.
Read Our Latest Analysis on BNTX
BioNTech Stock Down 0.8 %
Shares of BNTX traded down $0.89 during trading hours on Wednesday, hitting $114.70. The stock had a trading volume of 417,333 shares, compared to its average volume of 812,379. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21. The firm has a 50 day simple moving average of $113.83 and a 200-day simple moving average of $99.12. The firm has a market capitalization of $27.50 billion, a P/E ratio of -54.90 and a beta of 0.22. BioNTech SE has a 1-year low of $76.53 and a 1-year high of $131.49.
BioNTech (NASDAQ:BNTX - Get Free Report) last issued its earnings results on Monday, November 4th. The company reported $0.81 EPS for the quarter, beating the consensus estimate of ($1.26) by $2.07. The company had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $514.08 million. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The firm's revenue for the quarter was up 38.9% compared to the same quarter last year. During the same period last year, the business posted $0.73 EPS. Sell-side analysts predict that BioNTech SE will post -3.72 EPS for the current fiscal year.
BioNTech Profile
(
Free Report)
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.
Further Reading
Before you consider BioNTech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioNTech wasn't on the list.
While BioNTech currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
